CPI-006 Alone and in Combination With CPI-444 and With Pembrolizumab for Patients With Advanced Cancers

Conditions:   Non-Small Cell Lung Cancer;   Renal Cell Cancer;   Colorectal Cancer;   Triple Negative Breast Cancer;   Cervical Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Endometrial Cancer;   Sarcoma;   Squamous Cell Carcinoma of the Head and Neck;   Bladder Cancer;   Metastatic Castration Resistant Prostate Cancer
Interventions:   Drug: CPI-006;   Drug: CPI-006 + CPI-444;   Drug: CPI-006 + pembrolizumab
Sponsor:   Corvus Pharmaceuticals, Inc.
Not yet recruiting

http://ift.tt/2oLhrr8